Cargando…

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxicities. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Xinghua, Huang, Zhaoliang, Zhong, Tingting, Zhang, Peng, Wang, Zhongmin Maxwell, Xia, Michelle, Li, Baiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012886/ https://www.ncbi.nlm.nih.gov/pubmed/36872527 http://dx.doi.org/10.1080/19420862.2023.2180794

Ejemplares similares

Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report
por: Peng, Jieqiong, et al.
Publicado: (2022)

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023)

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
por: Tustian, Andrew D., et al.
Publicado: (2016)

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
por: Qiao, Qian, et al.
Publicado: (2023)

Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity
por: Tustian, Andrew D., et al.
Publicado: (2018)

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
por: Huang, Zhaoliang, et al.
Publicado: (2022)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model
por: Do, Tuan-Minh, et al.
Publicado: (2020)

Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
por: Yu, Lin, et al.
Publicado: (2021)

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023)

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
por: Berezhnoy, Alexey, et al.
Publicado: (2020)

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine
por: Tsuji, Isamu, et al.
Publicado: (2021)

Development of a Novel Tetravalent Synthetic Peptide That Binds to Phosphatidic Acid
por: Ogawa, Rina, et al.
Publicado: (2015)

Binding Revisited—Avidity in Cellular Function and Signaling
por: Erlendsson, Simon, et al.
Publicado: (2021)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
por: Chen, Peng-Yu, et al.
Publicado: (2023)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

The inverse-trans-influence in tetravalent lanthanide and actinide bis(carbene) complexes
por: Gregson, Matthew, et al.
Publicado: (2017)

Orchestrating Binding Interactions and the Emergence of Avidity Driven Therapeutics
por: Kapcan, Eden, et al.
Publicado: (2023)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Frequency and avidity of specific antigen-binding cells in developing mice
Publicado: (1975)

High-avidity binding drives nucleation of amyloidogenic transthyretin monomer
por: Gao, Li, et al.
Publicado: (2022)

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
por: Zhao, Yuanyuan, et al.
Publicado: (2023)

Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
por: Ollier, Romain, et al.
Publicado: (2019)

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
por: Metz, Silke, et al.
Publicado: (2012)

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab
por: Mak, Stefanie, et al.
Publicado: (2022)

Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity
por: Song, Jinyeop, et al.
Publicado: (2023)

Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs
por: Shi, Dan-Yang, et al.
Publicado: (2023)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
por: Scheuer, Werner, et al.
Publicado: (2016)

Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection
por: Yang, Huabing, et al.
Publicado: (2023)

Author Correction: The inverse-trans-influence in tetravalent lanthanide and actinide bis(carbene) complexes
por: Gregson, Matthew, et al.
Publicado: (2018)

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017)

Engineering Bispecificity into a Single Albumin-Binding Domain
por: Nilvebrant, Johan, et al.
Publicado: (2011)

Novel Decapeptides that Bind Avidly and Deliver Radioisotope to Colon Cancer Cells
por: Abraham, John M., et al.
Publicado: (2007)

Cholesterol enhances influenza binding avidity by controlling nanoscale receptor clustering
por: Goronzy, I. N., et al.
Publicado: (2018)

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
por: Benedetti, Filippo, et al.
Publicado: (2021)

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
por: Chen, Weimin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skr7lasfa5qlj9dlh5gnessi1p